ScienceDaily: Latest Science News

---

• New optogenetic tool for controlling neuronal signalling by blue light
• Drug shows promise for effectively treating metabolic syndrome
• Benefits of two drugs in treating type 1 diabetes compared
• 'Switch' in Alzheimer's and stroke patient brains prevents generation and survival of neurons
• Urgent need for Alzheimer's drug development identified: 99.6 percent of drug attempts fail

New optogenetic tool for controlling neuronal signalling by blue light Posted: 05 Jul 2014 11:00 AM PDT Scientists have developed a new technology in the field of optogenetics that can remotely control specific receptors by light. They have named this new technology "OptoTrk" and it has succeeded with neuronal differentiation inducement.

Drug shows promise for effectively treating metabolic syndrome Posted: 03 Jul 2014 11:24 AM PDT Researchers have discovered that an enzyme involved in intracellular signaling plays a crucial role in developing metabolic syndrome, a finding that has a spinoff company developing a drug to potentially treat the condition.

Benefits of two drugs in treating type 1 diabetes compared Posted: 03 Jul 2014 11:21 AM PDT Participants between the ages of 11 and 36 received either the two drugs or a placebo while continuing their insulin injections. The group receiving the drugs did not experience an improvement in insulin production, but some study participants whose GLP-1 and gastrin levels increased may have better preserved beta cell levels.

'Switch' in Alzheimer's and stroke patient brains prevents generation and survival of neurons Posted: 03 Jul 2014 09:52 AM PDT A new study finds a modification to the transcriptional protein MEF2 that inhibits the growth of new brain cells and survival of existing cells. The findings show promise for therapeutic intervention for a variety of neurodegenerative disorders.

Urgent need for Alzheimer's drug development identified: 99.6 percent of drug attempts fail Posted: 03 Jul 2014 07:26 AM PDT Researchers have conducted the first-ever analysis of clinical trials for Alzheimer's disease, revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments.

You are subscribed to email updates from Latest Science News -- ScienceDaily To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610